Publications by authors named "Christopher LaGanke"

Claim this Profile
D
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Christopher C LaGanke

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Colin M Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F Hunter, Christopher C LaGanke

Mult Scler J Exp Transl Clin· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass, Christopher LaGanke

Mult Scler· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Broad-Spectrum Dietary Supplementation on Quality of Life, Symptom Severity, and Functioning in Multiple Sclerosis.
H Reginald McDaniel, Christopher LaGanke, Laura Bloom, Sharon Goldberg, Judith Hensel

J Diet Suppl· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Robert T Naismith, Jerry S Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L Arnold

Mult Scler· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of a Polysaccharide-Based Multinutrient Dietary Supplementation Regimen on Infections and Immune Functioning in Multiple Sclerosis.
H Reginald McDaniel, Christopher LaGanke, Laura Bloom, Sharon Goldberg, Lucas C Lages

J Diet Suppl· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Tjalf Ziemssen, Ann D Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Christopher LaGanke

CNS Drugs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo, Christopher C LaGanke

Mult Scler· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis.
Angel Chinea, William David Honeycutt, Tamara Miller, Donna Graves, Alan Jacobs, Christopher C LaGanke

Int J MS Care· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D Bass, Christopher LaGanke

Front Neurol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.
Christopher LaGanke, Lawrence Samkoff, Keith Edwards, Lily Jung Henson, Pavle Repovic

Neurol Neuroimmunol Neuroinflamm· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Barry Singer, Daniel Bandari, Mark Cascione, Christopher LaGanke, John Huddlestone

BMC Neurol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis